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Chronic lymphocytic leukemia (CLL) patients with differentialsomatic hypermutation status of the immunoglobulin heavy vari-able genes, namely mutated or unmutated, display fundamental
clinico-biological differences. Considering this, we assessed prognosis
separately within mutated (M-CLL) and unmutated (U-CLL) CLL in 3015
patients, hypothesizing that the relative significance of relevant indica-
tors may differ between these two categories. Within Binet A M-CLL
patients, besides TP53 abnormalities, trisomy 12 and stereotyped subset
#2 membership were equivalently associated with the shortest time-to-
first-treatment and a treatment probability at five and  ten years after
diagnosis of 40% and 55%, respectively; the remaining cases exhibited
5-year and 10-year treatment probability of 12% and 25%, respectively.
Within Binet A U-CLL patients, besides TP53 abnormalities, del(11q)
and/or SF3B1mutations were associated with the shortest time-to-first-
treatment (5- and 10-year treatment probability: 78% and 98%, respec-
tively); in the remaining cases, males had a significantly worse prognosis
than females. In conclusion, the relative weight of indicators that can
accurately risk stratify early-stage CLL patients differs depending on the
somatic hypermutation status of the immunoglobulin heavy variable
genes of each patient. This finding highlights the fact that compartmen-
talized approaches based on immunogenetic features are necessary to
refine and tailor prognostication in CLL. 
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ABSTRACT
Introduction
Despite mounting evidence for the existence of distinct
biological variants of chronic lymphocytic leukemia
(CLL), the 2016 update of the World Health Organization
(WHO) classification still considers CLL as a single, homo-
geneous entity, in contrast to other hematologic malignan-
cies (e.g. diffuse large B-cell lymphoma, DLBCL) which
are segregated in different subgroups, based on the inte-
gration of genetic, morphological, immunophenotypic
and clinical features.1 
Since the introduction of the Rai and Binet clinical stag-
ing systems in the 1970s,2,3 it has become increasingly evi-
dent that the clinical heterogeneity in CLL is linked to and
reflects the underlying biological heterogeneity. Hence,
several initiatives have focused on identifying biomarkers
that would refine prognostication, especially for cases
who present with early stage disease, who nowadays rep-
resent the great majority of patients (80-85%).4-12
Consequently, numerous prognostic indices have been
proposed; however, none has been adopted in every-day
clinical practice.13 This is partly due to the fact that differ-
ent variables have been assessed in each evaluated cohort
while the actual routine diagnostic and monitoring prac-
tice varies between different institutions. Moreover, most
reported cohorts were rather small, thus inherently limit-
ed in their capacity to both encompass the remarkable
clinico-biological heterogeneity of CLL and reveal possible
interactions and interdependencies among the evaluated
prognosticators. 
The clonotypic B-cell receptor immunoglobulin (BcR IG)
is a unique molecular signature for every CLL clone, pres-
ent from its genesis and remaining unaltered throughout
the course of the disease, thus sharply contrasting other
tumor-derived biomarkers.14-19 Seminal studies from the
late 1990s have established that the somatic hypermuta-
tion (SHM) status of the immunoglobulin heavy variable
(IGHV) gene expressed by the clonotypic BcR IG is a
robust prognostic and predictive biomarker for CLL, 
stratifying patients into two non-interchangeable cate-
gories with different clinical behavior.20,21 More specifical-
ly, CLL with a significant SHM load (“mutated” CLL, M-
CLL) generally follow an indolent clinical course, whereas
CLL carrying no or few mutations (“unmutated” CLL, U-
CLL) generally have an aggressive disease and an overall
inferior response to chemoimmunotherapy.22-24 
This subclassification into M-CLL and U-CLL reflects
fundamental clinico-biological differences extending from
the genomic and epigenomic to the transcriptomic and
proteomic levels, alluding to distinct ontogeny and evolu-
tion patterns, including response to treatment, for the two
patient categories.14,24-27 That said, within both M-CLL and
U-CLL, a sizeable proportion of cases exhibit a clinico-bio-
logical behavior pattern that deviates from the expected,
thus highlighting that the heterogeneity of CLL persists
even within a given SHM category.28-31 The paradigmatic
example is offered by CLL subset #2, defined by the
expression of stereotyped IGHV3-21/IGLV3-21 BcR IG,
within which M-CLL cases follow an aggressive clinical
course similar to U-CLL.30,32,33 
Notably, other established prognosticators such as cyto-
genetic aberrations or recurrent gene mutations are asym-
metrically distributed within M-CLL or U-CLL.10,34-36 On
these grounds, it is not unreasonable to think that defini-
tive conclusions about the precise clinical implications of
any given biomarker should be drawn only after consider-
ing the SHM status of the clonotypic BcR IG. 
In this study, we followed a compartmentalized
approach where we assessed the prognostic impact of tra-
ditional and novel prognostic parameters separately with-
in M-CLL and U-CLL in a large multi-institutional cohort
of well characterized CLL patients, based on the hypoth-
esis that not all variables would carry equal weight within
the two SHM categories. Considering that the key chal-
lenge at the time of diagnosis is determining if, and conse-
quently when, early stage/asymptomatic patients will
require treatment, we focused on identifying a robust
prognostication scheme for time-to-first-treatment (TTFT)
in these separate disease categories. 
Methods
Patients’ characteristics
Overall, 2366 general practice patients with CLL diagnosed fol-
lowing the 2008 International Workshop on CLL (IWCLL) diag-
nostic criteria37 from 10 European institutions were included in
this multicenter retrospective study (Online Supplementary Table
S1). The external validation cohort comprised of 649 Binet A cases
evaluated at the Munich Leukemia Laboratory (n=508) and from a
Scandinavian population-based study (n=141) (Online
Supplementary Table S2). Ethical approval was granted by the local
review committees and informed consent was collected according
to the Declaration of Helsinki.
Methodologies
Detailed information about the methodologies used to analyze
the prognostic markers and definitions about stereotyped subsets
and the criteria for subset assignment are provided in the Online
Supplementary Appendix. Briefly: i) mutational screening was per-
formed for the following genes: NOTCH1, entire exon 34 or tar-
geted analysis for del7544-45/p.P2514Rfs*4; TP53, exons 4–8 but
also exons 9–10 for some centers; SF3B1, exons 14–16; BIRC3,
exons 6–9 and MYD88, exons 3 and 5 or targeted analysis for
p.L265P. The great majority (80%) of cases included in this study
were screened for the aforementioned recurrent mutations by
Sanger sequencing. In the remaining cases (20%), next generation
sequencing (NGS) was applied and only those clones with higher
than 10% variant allele frequency (VAF >10%) were considered;
ii) fluorescence in situ hybridization (FISH) was performed in 1825
(77%) cases using probes for the 13q14, 11q22, 17p13 regions and
trisomy 12 (cut off: 5%) while results were interpreted following
Döhner’s hierarchical model;38 and iii) sequence analysis and inter-
pretation of IGHV-IGHD–IGHJ rearrangements (including BcR IG
stereotypy) was performed as described previously.39  
Statistical analysis
We assessed the prognostic impact on TTFT of the following
variables: age at the time of diagnosis; sex; CD38 expression; cyto-
genetic aberrations [del(17p), del(11q), del(13q) and trisomy 12
(+12)]; mutations within the TP53, SF3B1, NOTCH1, BIRC3 and
MYD88 genes; and immunogenetic features, including borderline
germline identity (GI: 97-97.99%) and assignment to stereotyped
subsets #1, #2 and #4. 
The following methodology was applied separately for M-CLL
and U-CLL patients. The χ2 test was used to assess the homogene-
ity of all categorical prognostic variables within the different Binet
stages (A, B and C). In order to evaluate homogeneity and detect
significant differences within each categorical variable, the
Bonferroni correction was applied to adjust for multiple compari-
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son error and the significance level was set to P<0.017. TTFT was
evaluated from the diagnostic date until the date of initial treat-
ment; untreated cases were censored at the time of last follow up.
Survival curves were constructed using the Kaplan-Meier method,
and the log-rank test was applied to determine statistically signif-
icant differences between survival proportions. 
The univariable Cox regression model was used to determine
the most important prognostic factors. Multivariable Cox regres-
sion analysis was subsequently applied to evaluate the simultane-
ous effect of the important variables on TTFT. For the multivari-
able Cox analysis, we considered only those cases with available
data for all the factors included in the model (n=918 for M-CLL
and n=384 for U-CLL) on the grounds that imputing the values of
the biomarkers could introduce substantial bias. The same rule
was applied for the binary recursive partitioning. That said, no
major differences were observed between the entire cohort and
the proportion of cases included in the multivariable Cox analysis
(Online Supplementary Table S3); this suggests that the patients
included in the multivariable analysis were representative of the
entire cohort. 
The proportional hazard  assumption was assessed for both the
univariable and multivariable analysis. The stability of the multi-
variable Cox model was internally validated using a bootstrapping
procedure. Harrell’s C index was also calculated to further assess
the discriminatory power of the multivariable analysis when: a) all
important prognostic variables were included in the model; and b)
the resultant prognostic index was included in the model as the
sole prognostic variable (C=1 indicates perfect discrimination;
C=0.5 equates to chance).40
Binary recursive partitioning, based on the development of con-
ditional inference trees, was used to further validate the results of
Cox regression analysis.41 The patients were initially divided in
subgroups (terminal nodes) with different survival behavior. An
amalgamation algorithm was subsequently applied to merge the
terminal nodes that did not exhibit a significant difference in sur-
vival. All tests were two-sided and P<0.05 was considered statis-
tically significant. Statistical analyses were performed using the
Statistica Software 10.0 (StatSoftInc, Tulsa, OK, USA) and R-3.2.2.
Details are provided in the Online Supplementary Appendix. 
Results
Prognostic impact of clinical staging within M-CLL and
U-CLL
The median follow-up time for the entire cohort was
7.1 years (range, 0.1-33.1) with a median TTFT of 6.4
years (95%CI: 0.01-20.2 years) (Online Supplementary
Figure S1). As expected, in both M-CLL and U-CLL, Binet
A patients exhibited significantly longer TTFT compared
to Binet B and C cases (Figure 1). Most likely, this reflects
the sharp clinico-biological differences between Binet A
and Binet B/C patients while also underscoring the current
indications for treatment that broadly overlap with the cri-
teria for Binet stage B and C assignment (Online
Supplementary Tables S4 and S5). In keeping with previous
reports, M-CLL cases (n=1364, 58%) exhibited significant-
ly (P<0.0001) longer TTFT compared to U-CLL cases
(n=1002, 42%) (Online Supplementary Figure S2A).
Significant differences (P<0.0001) between M-CLL versus
U-CLL remained when the analysis was restricted to Binet
A cases (Online Supplementary Figure S2B). 
Prompted by these findings, and also considering that
Binet A cases predominated in both M-CLL and U-CLL
(90% and 67%, respectively), we focused our attention on
1900 Binet A cases (M-CLL: n=1224; U-CLL: n=676). We
refrained from investigating the impact of biomarkers
within Binet B/C cases since the limited number of cases
within each subgroup would not allow firm conclusions
to be drawn. 
Analysis for time-to-first-treatment within early stage
mutated chronic lymphocytic leukemia 
Univariable Cox regression analysis within M-CLL
Binet A cases (n=1224) revealed that male sex, CD38 pos-
itivity, +12, subset #2, TP53 abnormalities (TP53abn) and
borderline IGHV gene germline identity  (GI: 97-97.9%)
were associated with significantly shorter TTFT (Table 1).
Bordeline GI remained significant in the univariable analy-
sis even when subset #2 cases were excluded. TP53abn,
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Figure 1. Kaplan-Meier curves for time-to-first-treatment (TTFT). (A) In Binet A, B and C mutated chronic lymphocytic leukemia (M-CLL) patients and (B) Binet A, B
and C unmutated chronic lymphocytic leukemia (U-CLL) patients.
A B
+12, subset #2 membership and male sex retained inde-
pendent adverse prognostic significance in the multivari-
able analysis (n=918) (Table 1). Of note, TP53abn, +12 and
subset #2 membership identified 3 groups of almost mutu-
ally exclusive cases (altogether: n=153, 16% of all Binet A
M-CLL)  (Figure 2A) with no statistical differences in
TTFT (median TTFT for TP53abn, +12, subset #2: 5.4, 7.1
and 4.1 years respectively; P=0.19) (Figure 2B). 
To further validate the results of the Cox regression
analysis, we applied recursive partitioning models within
a conditional inference framework. TP53abn, +12 and sub-
set #2 membership were again identified as the most
important predictors since the 3 groups defined by these
predictors displayed similar TTFT that was significantly
shorter from the remaining Binet A M-CLL (Figure 3A). 
Analysis for time-to-first-treatment within early stage
unmutated chronic lymphocytic leukemia
Univariable Cox regression analysis revealed that
TP53abn, SF3B1 mutations, del(11q) and male sex had a
shorter TTFT within Binet-A U-CLL (n=676), while +12
had a longer TTFT (Table 1). TP53abn, SF3B1 mutations,
del(11q) and male sex retained significance in the multi-
variable analysis (n=384) (Table 1). TP53abn and/or SF3B1
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Table 1. Univariable and multivariable analysis for time-to-first-treatment within Binet A mutated chronic lymphocytic leukemia (M-CLL) and
unmutated chronic lymphocytic leukemia (U-CLL). Harrell’s C-index (standard error in parenthesis) was calculated  as 0.745  (se=0.013) and
0.753  (se=0.013) for the M-CLL and the U-CLL, respectively. Internal bootstrap validation for the multivariable analysis. Means of the Hazard
Ratio (HR), 95% Confidence Interval (CI) and percentage of selection within 1000 bootstrap samples are displayed per factor.
M-CLL/Binet A
Internal bootstrap validation
Univariable analysis (n=1224) Multivariable analysis (n=918) Factors (mean) Selection 
HR 95% CI P HR 95% CI P HR 95% CI percentage
Male 1.352 1.063-1.718 0.013 1.354 1.007-1.820 0.044 1.406 1.044-1.894 57%
Age >65 years 0.976 0.769-2.237 0.842 - - -
CD38 expression 2.017 1.474-2.760 <0.0001 1.058 0.678-1.652 0.801 1.048 0.666-1.648 8.4%
idel(13q) 0.761 0.573-1.010 0.059 - - -
+12 2.428 1.691-3.487 <0.0001 2.565 1.665-3.952 <0.0001 2.669 1.769-4.031 98.2%
del(11q) 2.010 0.944-4.281 0.071 - - -
TP53abn 3.347 2.175-5.151 <0.0001 2.685 1.607-4.485 0.0001 3.064 1.864-5.047 95.6%
NOTCH1 2.107 0.993-4.447 0.052 - - -
SF3B1 1.856 0.913-3.771 0.088 - - -
MYD88 1.551 0.680-3.538 0.296 - - -
GI:97-97.99% 1.571 1.069-2.308 0.021 0.988 0.568-1.717 0.966 0.940 0.529-1.679 3.4%
IGHV3-23 1.025 0.719-1.461 0.89 - - -
IGHV3-21* 1.466 0.605-3.555 0.396 - - -
Subset #2 3.384 1.594-7.181 0.001 3.268 1.155-9.244 0.025 3.885 1.353-12.267 62%
Subset #4 0.658 0.309-1.398 0.277 - - -
U-CLL/Binet A
U-CLL/Binet A Internal bootstrap validation
Univariable analysis (n=672) Multivariable analysis (n=384) Factors (mean) Selection 
HR 95% CI P HR 95% CI P HR 95% CI percentage
Male 1.341 1.106-1.626 0.028 1.610 1.229-2.109 0.0005 1.630 1.239-2.146 93.8%
Age >65 years 0.845 0.701-1-020 0.079 - - -
CD38 expression 1.144 0.832-1.575 0.405 - - -
del13q** 0.902 0.729-1.117 0.347 - - -
+12 0.751 0.568-0.993 0.045 0.898 0.632-1.274 0.547 0.912 0.640-1.299 10.4%
del(11q) 1.640 1.292-2.082 <0.0001 1.432 1.071-1.916 0.0151 1.475 1.098-1.983 69.1%
TP53abn 1.613 1.213-2.146 0.001 2.357 1.548-3.589 <0.0001 1.475 1.098-1.983 69.1%
NOTCH1 1.142 0.874-1.493 0.328 - - -
SF3B1 1.892 1.335-2.682 <0.0001 1.624 1.129-2.337 0.008 1.682 1.159-2.442 73.4%
BIRC3 1.206 0.532-2.732 0.652 - - -
GI:100% 1.231 0.993-1.524 0.056 - - v
IGHV1-69 1.190 0.959-1.457 0.112 - - -
Subset #1 1.382 0.939-2.033 0.099 - - -
CD38 expression: positivity >30%; idel(13q): isolated deletion of chromosome 13q; +12: trisomy 12; del(11q): deletion of chromosome 11q; TP53abn: deletion of chromosome
17p (del(17p)) and/or TP53 mutation; GI: germline identity; IGHV3-23: usage of IGHV3-23; IGHV3-21*: usage of IGHV3-21 non subset #2; subset #2: assignment to stereotyped sub-
set #2; subset #4: assignment to stereotyped subset #4. **Due to the low number of cases with available data for all abnormalities detected by fluorescence in situ hybridization
(FISH), deletion of chromosome 13q was used instead of idel(13q) for the U-CLL cohort. 
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Figure 3. Application of binary recursive partitioning in mutated chronic lymphocytic leukemia (M-CLL) and unmutated chronic lymphocytic leukemia (U-CLL).  (A)
Decision tree for Binet A M-CLL based on binary recursive partitioning and the subsequent application of an amalgamation algorithm. Trisomy 12 (+12), TP53abn
and subset #2 membership were found to be the most significant factors as determined by the partitioning algorithm. The Binet A population is split in 4 terminal
nodes (4, 5, 6 and 7). The amalgamation algorithm applied subsequently merged 3 of them in a larger terminal node. In particular, +12 was considered as the co-
variate with the strongest association to time-to-first-treatment (TTFT). Amongst patients lacking +12, TP53abn was the co-variate with the strongest association to
TTFT and so on. After applying the amalgamation algorithm, patients with +12 and/or TP53abn and/or assignment to subset #2 were grouped into a larger node,
resulting in 2 terminal nodes. The splitting is performed from right to left, following the criterion of strongest factor association with TTFT. The right branch represents
the presence of a particular factor and the left branch the absence of that factor. P-value corresponds to a log-rank scores based test. The Kaplan-Meier curves esti-
mate the TTFT of patients within each terminal node and n represents the number of patients per node. (B) Decision tree for Binet A U-CLL based on binary recursive
partitioning and the subsequent application of an amalgamation algorithm. Male sex, TP53abn and del(11q) were the most significant factors as determined by the
partitioning algorithm. The Binet A population was split into 6 terminal nodes (4, 5, 6, 9, 10 and 11). The amalgamation algorithm applied merged 3 of the terminal
nodes into a larger terminal node. Sex was deemed to be the co-variate with the strongest association to TTFT. Amongst male patients, TP53abn was the co-variate
with strongest association to TTFT. Amongst female patients, del(11q) was the co-variate with strongest association to TTFT and so on. After applying the amalga-
mation algorithm, male patients without TP53abn and with del(11q), and female patients with del(11q) and/or TP53abn were grouped into a larger node. The final
number of terminal nodes was 4. The splitting is performed from top to bottom, following the criterion of strongest factor association with TTFT. The right branch rep-
resents the presence of a particular factor and the left one the absence of that factor. P-value corresponds to a log-rank scores-based test. The Kaplan-Meier curves
estimate the TTFT of patients within each terminal node and n represents the number of patients per node. 
Figure 2. Subgroups of patients with similar prognosis within mutated chronic lymphocytic leukemia (M-CLL) and unmutated chronic lymphocytic leukemia (U-CLL).
(A) TP53abn, trisomy 12 (+12) and stereotyped subset #2 assignment define three almost non-overlapping groups within early stage M-CLL. (B) Binet A M-CLL cases
with TP53abn, +12 or assignment to stereotyped subset #2 display similar time-to-first-treatment (TTFT.) (C) Distribution of TP53abn, SF3B1 mutations and del(11q)






mutations and/or del(11q) [TP53abn/SF3B1mut/del(11q)]
were positive in 146 cases (42% of the evaluated cohort
with available data for all 3 parameters) (Figure 2C) and
exhibited a similar TTFT (median TTFT for TP53abn,
SF3B1mut, del(11q): 1.8, 2.8 and 2.1 years, respectively;
P=0.47) (Figure 2D). The co-occurrence of these aberra-
tions was not found to aggravate the prognosis when
compared to single aberrations alone (Online
Supplementary Figure S3). Male sex was associated with a
shorter TTFT (median TTFT: 3.9 years, 95%CI: 0.1-5.9
years) amongst non-TP53abn/SF3B1mut/del(11q) U-CLL
cases (Online Supplementary Figure S4). 
Similar to M-CLL, we applied recursive partitioning
(Figure 3B) which highlighted TP53abn, del(11q) and male
sex as the most important variables within Binet A U-CLL.
SF3B1 mutations did not reach significance, potentially
due to the low number of cases with isolated SF3B1muta-
tions at the stage of the final nodes. In short, the evaluated
U-CLL Binet A cohort was allocated to subgroups with
differing TTFT, from shorter to longer, as follows: males
with TP53abn; males with del(11q)/females with TP53abn
and/or del(11q); males without TP53abn/del(11q); and,
females without TP53abn/del(11q).
Two somatic hypermutation categories of chronic 
lymphocytic leukemia  patients, two prognostic indices
for time-to-first-treatment
Based on the above, we developed two prognostic
indices for assessing TTFT, tailored to each SHM category.
Within M-CLL, we defined 4 groups based on their clini-
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Figure 4. Prognostic index for time-to-first-treatment (TTFT) for mutated chronic lymphocytic leukemia (M-CLL) and unmutated chronic lymphocytic leukemia (U-
CLL). (A) Prognostic index for TTFT within M-CLL: i) very high risk: Binet C; ii) high risk: Binet B; iii) intermediate risk: Binet A with at least one of the following: TP53abn
or +12 or assignment to subset #2 and; iv) low risk: non-TP53abn/+12/#2 Binet A. (B) Prognostic index for TTFT within U-CLL: i) very high risk: Binet C; ii) high risk:
Binet B; iii) intermediate risk: Binet A with at least  one of the following: TP53abn or +SF3B1 mutations or del(11q) membership; iv) low risk: 
non-TP53abn/SF3B1mut/del(11q) male Binet A and; v) very low risk: non-TP53abn/SF3B1mut/del(11q) female Binet A.
Figure 5. Kaplan-Meier curves for time-to-first-treatment (TTFT) in the validation cohort. (A) Within mutated chronic lymphocytic leukemia (M-CLL), Binet A cases
positive for TP53abn, trisomy 12 (+12) and stereotyped subset #2 assignment display similar TTFT. (B) No difference regarding TTFT among Binet A and unmutated
chronic lymphocytic leukemia (U-CLL) cases carrying TP53abn, SF3B1 mutations or del(11q) in the validation cohort. 
A B
A B
co-biological profiles at the time of diagnosis: i) very high
risk: Binet C with identical 5- and 10-year treatment-prob-
ability (TP) of 92%; ii) high risk: Binet B, 5y-TP and 10y-
TP: 64% and 84%, respectively; iii) intermediate risk:
Binet A with one of the following: TP53abn and/or +12
and/or subset #2 membership, 5y-TP and 10y-TP: 40%
and 55%, respectively. [Of note, among 18 non-censored
cases with no treatment indication for more than 10 years
after diagnosis, 5 (30%) carried TP53abn]; and iv) low risk:
non-TP53abn/+12/subset #2 Binet A, 5y-TP and 10y-TP:
12% and 25%, respectively (Figure 4A). Harrell’s C Index
was calculated for the multivariable Cox model with the
prognostic index above being the sole predictor and was
found to equal 0.745  (se = 0.013).
In U-CLL, we could define 5 groups: i) very high risk:
Binet C with 5- and 10-year TP of 100%; ii) high risk:
Binet B, 5y-TP and 10y-TP: 90% and 100%, respectively;
iii) intermediate risk: Binet A with one of the following:
TP53abn and/or SF3B1mut and/or del(11q), 5y-TP and
10y-TP: 78% and 98%, respectively; v) low risk: non-
TP53abn/SF3B1mut/del(11q) male Binet A, 5y-TP and 10y-
TP: 65% and 85%, respectively; and iv) very low risk:
non-TP53abn/SF3B1mut/del(11q) female Binet A, 5y-TP
and 10y-TP: 45% and 65%, respectively (Figure 4B).
Harrell’s C Index was calculated for the multivariable Cox
model with the prognostic index being the sole predictor
and was found to equal 0.753  (se = 0.013).
Internal validation
In order to validate the results mentioned above, a boot-
strapping procedure was performed. In early stage M-CLL
patients, this showed that the average number of predic-
tors included in the multivariable Cox model was 3.2 with
three variables exhibiting selection percentages greater
than 60%, i.e. TP53abn, +12 and subset #2 (Table 1). In
early stage U-CLL patients, bootstrapping showed that
the average number of predictors considered significant in
the multivariable Cox model was 3.5. Four variables
exhibited selection percentages greater than 60%, i.e.
TP53abn, SF3B1mut, del(11q) and male sex. 
External validation
Application of the above mentioned indices to the vali-
dation cohort (n=649) led to the following observations: i)
in M-CLL, TP53abn, +12 and subset #2 membership (inter-
mediate risk for M-CLL) exhibited similar TTFT, consti-
tuting a group (16% of all Binet cases also in the validation
cohort) with almost identical 5y-TP (43%) and 10y-TP
(60%) to those observed in the training cohort (40% and
55%, respectively) (Figure 5A); ii) similarly, in U-CLL, no
difference was observed in TTFT for Binet A cases carry-
ing TP53abn and/or SF3B1mut and/or del(11q) (intermedi-
ate risk for U-CLL) who exhibited similar 5y-TP and 10y-
TP to that of the training cohort (74% vs. 78% and 92%
vs. 98%, respectively; P-values: non significant) (Figure
5B); iii) amongst the remaining non-
TP53abn/SF3B1mut/del(11q) U-CLL Binet A cases, the dif-
ference between male and female patients did not reach
statistical significance (P=0.2) (Online Supplementary Figure
S5A and B).
Discussion
Chronic lymphocytic leukemia constitutes a rather
unique case amongst cancers in that the great majority of
patients are asymptomatic at diagnosis and classified as
early stage, and thus do not require immediate
treatment.42 However, most patients will progress and
meet the criteria for treatment initiation albeit at a vari-
able time from diagnosis.37,42 Therefore, accurate predic-
tion of the TTFT is of major importance for both patients
and physicians having to address the challenge of living
with and managing this (largely) invisible and incurable
disease. In support of this argument, solid prognostica-
tion is increasingly recognized as both a priority and an
unmet need by CLL patients themselves, who would
benefit from accurate prognostic information in order to
make educated life choices and, perhaps, also participate
more actively in their care. 
Several prognostic models have been developed for CLL
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Figure 6. Kaplan-Meier curves for time-to-first-treatment (TTFT) for mutated chronic lymphocytic leukemia (M-CLL) and unmutated chronic lymphocytic leukemia
(U-CLL) cases carrying trisomy 12 (+12). (A) +12 is an unfavorable prognosticator in M-CLL. (B) +12 is associated with a more indolent clinical course in U-CLL.
A B
based on combinations of biomarkers and host-derived
features. However, none has been adopted in everyday
clinical practice,13 e.g. to help decide about the follow-up
strategy amongst untreated patients. These indices were
mainly based on Cox regression models, where each
respective training/validation cohort was considered as a
single group. Herein, we followed a novel approach eval-
uating prognosis separately within M-CLL and U-CLL
focusing on TTFT in the largest ever series studied to this
purpose. We report that within early stage M-CLL,
TP53abn, +12 and assignment to stereotyped subset #2
identified a subgroup of patients with uniformly shorter
TTFT compared to the remaining early Binet A M-CLL.
Similarly, within U-CLL the presence of TP53abn, del(11q)
and SF3B1mutations was found to be associated with the
shortest TTFT, whereas the remaining U-CLL female
patients had a significantly longer TTFT compared to
males. 
Classification of CLL patients based on the SHM status
of the clonotypic BcR IG into M-CLL and U-CLL cate-
gories offers robust prognostic information, differing from
other prognostic markers (e.g. genetic aberrations) that
may evolve over time.15,17,18,43 Of note, studies by us and
others have documented an asymmetric distribution of
certain genetic aberrations in patients with distinct
immunogenetic features extending from the M-CLL or U-
CLL categorization to different stereotyped subsets.32,44,45
This has prompted speculation that particular modes of
immune signaling initiated by specific BcR IG may trigger
different pathways of clonal evolution leading to the
emergence of distinct disease variants.  
For these reasons, the BcR IG appears an obvious start-
ing point for developing a biologically-orientated prognos-
tication scheme for CLL, as in our present study, offering
the possibility to dissect the precise impact of a given bio-
marker within a particular immunogenetic category (e.g.
M-CLL or U-CLL). For example, within M-CLL, +12 was
found to define a subgroup of patients with a TTFT simi-
lar to that of patients harboring TP53abn, whereas, in con-
trast, +12 was associated with favorable outcome within
U-CLL (Figure 6A and B). Of note, mutations within the
NOTCH1 gene had no impact on survival among U-CLL
cases with +12 (Online Supplementary Figure S6). These
findings may explain: i) why +12 is considered as an inter-
mediate-risk aberration in prognostic indices where CLL is
evaluated as one group regardless of the SHM status;38
and, ii) the contradictory results reported in different
cohorts with different relative proportion of M-CLL and
U-CLL patients, regarding the significance of a given indi-
cator that can show an asymmetric distribution within
each SHM group. 
Our initial results based on Cox regression analysis
were validated internally, being highly reproducible in an
independent validation cohort. In particular, the median
TTFT for the subgroups of patients with the shortest
TTFT in both SHM categories, namely TP53abn/+12/#2
and TP53abn/SF3B1mut/del(11q) for M-CLL and U-CLL
respectively, was almost identical between the validation
and the training cohort. Interestingly, the latter exhibited
significant differences in terms of the biological back-
ground compared to the training cohort (Online
Supplementary Table S2); this may be taken as further evi-
dence for the robustness of our approach, since similar
results were obtained across cohorts with differing patient
composition. Cox regression results were further con-
firmed through the application of an alternative statistical
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Figure 7. Prognostic algorithm regarding treatment probability for chronic lymphocytic leukemia (CLL). 5y-TP: treatment probability five years from diagnosis; 10y-
TP: treatment probability ten years from diagnosis; U-CLL: CLL with unmutated IGHV genes; M-CLL: CLL with mutated IGHV genes; TP53abn: deletion of chromosome
17p (del(17p)) and/or TP53 mutation; +12:trisomy 12, del(11q): deletion of chromosome 11q; SF3B1mut: SF3B1 mutation; #2: assignment to stereotyped subset
#2. The pie chart refers to the entire cohort with each slice indicating the proportion of patients according to Binet clinical staging.
approach, namely binary recursive partitioning, which
offers a different framework, thereby conveying a hierar-
chical order of importance and classification for the evalu-
ated prognostic factors. 
Admittedly, despite providing a robust risk stratification
scheme, the  prognostic indices proposed here will not
solve the problem of outliers, while they also overlook the
potential effect of other variables with proven prognostic
significance, e.g. cytogenetic complexity or methylation
signatures. Thus, they cannot be considered the last word
in biomarker-orientated risk stratification for TTFT. They
do, however, highlight the need for further studies, while
providing the conceptual frame of compartimentalization.
It should be further emphasized that our approach is built
on the pivotal role of IGHV SHM status in the prognostic
setting, which appears to be less important in the era of
novel agents, namely BTK and BCL2 inhibitors, where
response rates seem to be similar between M-CLL and U-
CLL.46,47
Recently, the International Prognostic Index for patients
with CLL (CLL-IPI) was developed for assessing overall
survival (OS).7 This has provided a robust prognostic clas-
sification scheme as it includes well-characterized
patients followed in the context of clinical trials. A caveat
of CLL-IPI concerns the fact that the evaluated patients
had been treated with various regimens in the context of
different clinical trials. Moreover, CLL-IPI does not allow
the identification of distinct groups within each SHM cat-
egory. For example, following the CLL-IPI score, a young
(<65 years), early-stage patient, negative for TP53abn and
belonging to M-CLL would never be characterized as
very high risk. It is important to note, therefore, that the
clinically aggressive stereotyped subset #2 would be over-
looked by the CLL-IPI as it largely falls into the category
of M-CLL cases lacking TP53abn, with 60% of patients
also under 65 years of age. This is not a trivial issue, con-
sidering that subset #2 accounts for up to 5% of all CLL
requiring treatment and, therefore, is equal in size to the
CLL-IPI very high risk group with very limited if any
overlap.30 A final, more general concern is that CLL-IPI
was developed based on the analysis of cases treated
prior to the introduction of novel therapies, which are
likely to change the treatment expectations and OS in
CLL, thus eventually creating the need for new predictive
schemes.48 
Our study identified subset #2 membership and SF3B1
mutations as prognostically important biomarkers for
early-stage M-CLL and U-CLL, respectively. In contrast,
other recurrent gene mutations such as NOTCH1 or
BIRC3 failed to reach significance even in univariable
analysis. Interestingly, SF3B1 mutations are remarkably
enriched within subset #2 (approx. 50% of cases harbor a
mutation), however, their impact within this very aggres-
sive subset remains equivocal.30,32 Overall, these results
emphasize the value of investigating IG sequences for
stereotyped subset #2 membership (easily determined
through the use of a free online tool available at:
http://bat.infspire.org/arrest/assignsubsets/49) and searching for
SF3B1 mutations in routine clinical practice as this would
enable a more accurate assessment of prognosis (TTFT) at
diagnosis of CLL. 
In conclusion, we propose a novel approach to prognos-
tic assessment in CLL grounded on the fact that not all
CLL are equal, but instead that M-CLL and U-CLL cate-
gories are fundamentally different regarding their ontoge-
ny and molecular landscape, at least for early-stage
patients (Figure 7). Our results support that compartmen-
talizing CLL with the BcR IG as the starting point allows
accurate prognostication in early-stage CLL. This further
shows that the relative weight of well established prog-
nostic indicators differs based on the immunogenetic fea-
tures of each individual case. From a broader perspective,
such compartmentalized approaches might prove relevant
in other B-cell lymphomas as well e.g. diffuse large B-cell
lymphoma where different biomarkers are emerging as
prognostically relevant for the activated B-cell or the ger-
minal center subtype, respectively,50 that display distinct
immunogenetic features and signaling signatures.50
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